DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Pediatrics
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Ultrasound Homepage

Hologic puts forth $85 million offer to buy SuperSonic Imagine An entry into cart-based breast ultrasound market

MR and ultrasound biopsies combined can detect prostate cancers, says study Detect up to 33 percent more tumors together

Fujifilm SonoSite brings new workflow solution to point of care ultrasound Addressing top priorities to reduce administrative burden on providers

New dye helps control 'lighting' for sharper images of heart May help identify early signs of heart disease

Ultrasound market gets supercharged by AI, cloud, and greater portability: report Generated $6.12 billion in 2018, and more growth expected

Verasonics settles legal dispute over software with SuperSonic Imagine Alleged patent infringement and misappropriate of trade secrets

Handheld ultrasound market poised for next wave of growth Insights from the market analysts at Signify Research

VisualDx to develop decision support platform for ultrasound in space Provide basic guidance on ultrasound interpretation

Breaking barriers in Alzheimer’s disease with focused ultrasound Researchers at Sunnybrook in Toronto are closing the therapeutic gap

Purchasing insights for cardiac ultrasound Guidance from the market experts at MD Buyline

EDAP TMS SA is now the exclusive
distributor of Theraclion's Echopulse system
in France

Theraclion taps EDAP to distribute HIFU system throughout France

by John R. Fischer , Staff Reporter
Theraclion has chosen EDAP TMS SA to be the exclusive distributor of its Echopulse system in France, as part of a new agreement between the two companies.

The noninvasive ablation solution for breast fibroadenomas and benign thyroid nodules is now available to customers with a new option that allows the system to operate as a mobile pay-per-use solution.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



“We just had approval from the French health care system to actually reimburse our benign breast tumor noninvasive solution,” David Caumartin, CEO of Theraclion, told HCB News. “We wanted to partner with someone who already had a pay-per-use business unit, which was the case with EDAP and therefore, it was natural combination for us to work with them to be able to make an echotherapy standard of care for benign breast tumors.”

The Echopulse system uses EDAP’s proprietary HIFU technology to treat breast fibroadenomas and benign thyroid nodules. Treatment with the system can take between 15 and 45 minutes.

The agreement allows EDAP France to expand the use of HIFU technology outside the field of urology. Through the reimbursement, Theraclion gains ten new sites in France.

The mobile pay-per-use solution will assist in the quick implementation of the Forfait Innovation cost-effectiveness study, which compares Echopulse echotherapy to surgery in the treatment of breast fibroadenoma, and will enable quick access among patients to thyroid echotherapy.

“Theraclion is the only one that can propose noninvasive ablation for benign thyroid and benign breast tumors,” he said. “We are proposing this in an outpatient fashion, without general anesthetic, just local. We basically destroy soft tissue lesions in 15, 30, 45 minutes of treatment time in a single session.”

Theraclion’s echotherapy procedure was recently was listed on the website of the British National Institute for Health and Clinical Excellence with guidance on its interventional procedures program (IPP) for the noninvasive treatment of breast fibroadenoma, and also received regulatory approval from the Russian Ministry of Health.

The system has been CE marked since 2012 and is available in Europe and Asia with key markets in Germany and Hong Kong. It is currently undergoing two clinical trials at four sites in the U.S.

Ultrasound Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2019 DOTmed.com, Inc.
ALL RIGHTS RESERVED